Hillhouse Capital Management, Quan Capital Spearhead NextCure’s $93 Million Series B

Biopharmaceutical firm NextCure Inc. has revealed that Quan Capital and Hillhouse Capital Management lead the investor roster as the company finishes its series B financial round. Additional series B investors backing the immunotherapy-focused Maryland company include ArrowMark Partners, Ping An Ventures, Surveyor Capital, Taiho Ventures, Bay City Capital and NS Investment...